Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment

Preliminary clinical trial data suggest a favourable benefit–risk profile for remdesivir vs placebo; however, current data are limited. One study reported shorter time to recovery (11 vs 15 days), with non-significant reduced mortality risk (8% vs 12%).

Source:

Drug Safety